株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ソラフェニブの中国市場:2010年〜2019年

Investigation Report on China Sorafenib Market, 2010-2019

発行 China Research and Intelligence 商品コード 335239
出版日 ページ情報 英文 20 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
ソラフェニブの中国市場:2010年〜2019年 Investigation Report on China Sorafenib Market, 2010-2019
出版日: 2015年07月10日 ページ情報: 英文 20 Pages
概要

2014年の中国におけるソラフェニブの販売額は1億6,500万人民元となり、前年の1億4,700万人民元から12.24%の増加となりました。同国では、環境汚染の悪化やライフスタイルの変化によって、肝臓癌の罹患率が拡大傾向にあり、ソラフェニブの需要が急増しています。現在、中国市場で入手できるソラフェニブは全てBayer AG製のものとなっています。

当レポートでは、中国のソラフェニブの市場について調査しており、ソラフェニブの効能・効果、中国市場における特許および承認の状況、売上・販売量の推移と予測、価格動向、主要メーカーと市場シェア、競合環境とその展望、主要メーカーのプロファイルなどをまとめています。

第1章 ソラフェニブの関連概念

  • 適応
  • 世界市場における販売状況

第2章 中国におけるソラフェニブの市場プロファイル

  • 特許および承認情報
  • 主要製薬会社
  • 市場規模

第3章 中国におけるソラフェニブの販売状況調査

  • 販売額
    • 総販売額
    • 地域別の販売額
  • 販売量
    • 総販売量
    • 地域別の販売数

第4章 中国におけるソラフェニブの主要製薬会社の市場シェア調査

  • 販売額ベースの市場シェア
  • 販売量ベースの市場シェア

第5章 中国におけるソラフェニブの剤形に関する調査

  • 剤形別の市場シェア:販売額ベース
  • 剤形別の市場シェア:販売量ベース

第6章 中国の病院におけるソラフェニブの基準価格

  • Bayer Pharma AG (商品名:Nexavar)

第7章 中国市場におけるソラフェニブの主要製薬会社

第8章 ソラフェニブ市場の見通し

  • 市場規模の予測
  • 競合情勢の予測
目次
Product Code: 1507270

The incidence of liver cancer and kidney cancer in China grows gradually. According to the Guidelines for Kidney Cancer Diagnosis and Treatment in China (the 2013 version), kidney cancer accounts for 2%-3% of adult malignant tumors in China and reports an obvious rise in incidence in recent years in China. Kidney cancer has surpassed bladder cancer to become the first in death related with urological tumors with its incidence growing at an average rate of 6.5% during the past two decades. According to the World Cancer Report 2014, China ranked first in the new cases of liver cancer and its death toll. Currently, liver cancer, with 0.257 in 1 million suffering from it, has become the third malignant tumor after stomach cancer and lung cancer in terms of mortality. As a novel small molecular multi-targeted inhibitor of tyrosine kinase, sorafenib is approved by FDA to treat unresectable advanced renal cell carcinoma and unresectable or metastasized primary hepatocellular carcinoma. Co-developed by Bayer and Onyx Pharmaceuticals, sorafenib got imported drug license in 2006 and was approved by China Food and Drug Administration to enter the market for the treatment of liver cancer in 2008.

According to CRI's survey on 20 sample hospitals in key regions in China, sales value of sorafenib was CNY 147 million in 2013 and CNY 165 million in 2014, increasing 12.24% year on year.

With the degradation of environmental pollution and changes in lifestyle, the incidence of liver cancer keeps rising. Hence the vast demand for sorafenib in China. Currently, sorafenib in the Chinese market all come from Bayer AG i.e. Bayer enjoys a market share of 100%.

Readers can get at least the following information from this report:

  • market size of sorafenib in China
  • major manufacturers of sorafenib in Chinese market
  • retail price of sorafenib in China
  • market outlook of sorafenib in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-tumor drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Sorafenib

  • 1.1. Indication
  • 1.2. Sales in Global Market

2. Market Profile of Sorafenib in China

  • 2.1. Patent and Approval Information of Sorafenib in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Sorafenib in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Sorafenib in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Sorafenib in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Sorafenib in Chinese Hospitals in 2014

  • Bayer Pharma AG (Trade Name: Nexavar)

7. Major Manufacturers of Sorafenib in Chinese Market, 2010-2014

8. Outlook of Sorafenib Market in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Status of Sorafenib in China
  • Chart Approval Information of Sorafenib in China
  • Chart Sales Status of Sorafenib in China
  • Chart Sales Value of Sorafenib in China, 2010-2014
  • Chart Sales Value of Sorafenib in Some Regions in China, 2010-2014
  • Chart Sales Volume of Sorafenib in China, 2010-2014
  • Chart Sales Volume of Sorafenib in Some Regions in China, 2010-2014
  • Chart Market Share of Sorafenib Manufacturers for Sales Value in China, 2010-2014
  • Chart Market Share of Sorafenib Manufacturers for Sales Volume in China, 2010-2014
  • Chart Sales Volume and Market Share of Bayer Pharma AG in China, 2010-2014
  • Chart Sales Value and Market Share of Sorafenib Tablets in China, 2010-2014
  • Chart Sales Volume and Market Share of Sorafenib Tablets in China, 2010-2014
  • Chart Price of Sorafenib Made by Bayer Pharma AG in Some Chinese Cities in 2014
Back to Top